Faculty / Research

Shinya Shibutani, PhD

Research Professor 


PhD, Toyama Medical and Pharmaceutical University, Japan

Postdoctoral, Fuji Chemical Industry Co., Ltd., Japan

631-444-7849  shinya.shibutani@stonybrook.edu
Carcinogenic Mechanism of Drugs

An increased risk of breast, ovarian, or endometrial cancer has been observed in women receiving hormone replacement therapy. Similar risk has also been detected in women treated with tamoxifen for breast cancer therapy or chemoprevention. My research focuses on establishing the carcinogenic mechanisms of estrogens or tamoxifen and evaluating the genotoxicity of these drugs to humans. Based on the carcinogenic mechanism of these drugs, we create a basis for developing safer agents. Such strategies could provide significant benefit for improving women health.

Kim, S. Y., Suzuki, N., Y. R. Santosh Laxmi, and Shibutani, S. Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab. Rev. 36, 199-218 (2004).

Kim, S. Y., Y. R. Santosh Laxmi, Suzuki, N., Ogura, K., Watabe, T., Duffel, M. W., and Shibutani, S. Formation of tamoxifen-DNA adducts via O-sulfonation, not O-acetylation, of alpha-hydroxytamoxifen in rat and human livers. Drug Metab. Dispos. 33, 1673-1678 (2005).

Yasui, M., Suzuki, N., Liu, X., Okamoto, Y., Kim, S. Y., Y. R. Santosh Laxmi, and Shibutani, S. Mechanism of translesion synthesis past an equine estrogen-DNA adduct by Y-family DNA polymerases. J. Mol. Biol. 371, 1151-1162 (2007).

Okamoto, Y., Liu, X., Suzuki, N., Okamoto, K., Kim, H. J., Y. R. Santosh Laxmi, Sayama, K., and Shibutani, S. Equine estrogen-induced mammary tumors in rats. Toxicol. Lett. 193, 224-228 (2010).

Y. R. Santosh Laxmi, Liu, X., Suzuki, N., Kim, S. Y., Okamoto, K., Kim, H. J., Zhang, G., Chen, J. J., Okamoto, Y., and Shibutani, S. Anti-breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions. Int. J. Cancer 127, 1718-1726 (2010).